Rapid and long-term response of pulmonary pleomorphic carcinoma to nivolumab

Satoru Senoo; Takashi Ninomiya; Go Makimoto; Kazuya Nishii; Hirohisa Kano; Hiromi Watanabe; Yusuke Hata; Toshio Kubo; Takehiro Tanaka; Katsuyuki Hotta; Yoshinobu Maeda; Katsuyuki Kiura

doi:10.2169/internalmedicine.0890-18

Rapid and long-term response of pulmonary pleomorphic carcinoma to nivolumab

Satoru Senoo, Takashi Ninomiya, Go Makimoto, Kazuya Nishii, Hirohisa Kano, Hiromi Watanabe, Yusuke Hata, Toshio Kubo, Takehiro Tanaka, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

Pulmonary pleomorphic carcinoma (PPC) is a rare very aggressive subtype of non-small cell lung cancer. We herein report a case of PPC that showed a rapid response to nivolumab. The patient, whose multiple tumors had progressed very aggressively, was treated with nivolumab, an anti-programmed cell death-1 (PD-1) antibody. The tumors dramatically shrank after one cycle of nivolumab. The tumors were positive for programmed cell death ligand 1 (PD-L1). An immunohistochemical analysis revealed numerous PD-1+, CD68+ and CD206+ macrophages. This PD-1 antibody may be a good treatment option, especially in tumors that express PD-L1 and which show PD-1+ macrophage infiltration.

Original language	English
Pages (from-to)	985-989
Number of pages	5
Journal	Internal Medicine
Volume	58
Issue number	7
DOIs	https://doi.org/10.2169/internalmedicine.0890-18
Publication status	Published - 2019

Keywords

FGFR
Immune checkpoint inhibitor
PD-1
PD-L1
Pulmonary pleomorphic carcinoma

ASJC Scopus subject areas

Internal Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2169/internalmedicine.0890-18

Cite this

@article{9e8073aa520c4ea1832e36335c80ccfa,

title = "Rapid and long-term response of pulmonary pleomorphic carcinoma to nivolumab",

abstract = "Pulmonary pleomorphic carcinoma (PPC) is a rare very aggressive subtype of non-small cell lung cancer. We herein report a case of PPC that showed a rapid response to nivolumab. The patient, whose multiple tumors had progressed very aggressively, was treated with nivolumab, an anti-programmed cell death-1 (PD-1) antibody. The tumors dramatically shrank after one cycle of nivolumab. The tumors were positive for programmed cell death ligand 1 (PD-L1). An immunohistochemical analysis revealed numerous PD-1+, CD68+ and CD206+ macrophages. This PD-1 antibody may be a good treatment option, especially in tumors that express PD-L1 and which show PD-1+ macrophage infiltration.",

keywords = "FGFR, Immune checkpoint inhibitor, PD-1, PD-L1, Pulmonary pleomorphic carcinoma",

author = "Satoru Senoo and Takashi Ninomiya and Go Makimoto and Kazuya Nishii and Hirohisa Kano and Hiromi Watanabe and Yusuke Hata and Toshio Kubo and Takehiro Tanaka and Katsuyuki Hotta and Yoshinobu Maeda and Katsuyuki Kiura",

note = "Publisher Copyright: 10.2169/internalmedicine.0890-18.",

year = "2019",

doi = "10.2169/internalmedicine.0890-18",

language = "English",

volume = "58",

pages = "985--989",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "7",

}

TY - JOUR

T1 - Rapid and long-term response of pulmonary pleomorphic carcinoma to nivolumab

AU - Senoo, Satoru

AU - Ninomiya, Takashi

AU - Makimoto, Go

AU - Nishii, Kazuya

AU - Kano, Hirohisa

AU - Watanabe, Hiromi

AU - Hata, Yusuke

AU - Kubo, Toshio

AU - Tanaka, Takehiro

AU - Hotta, Katsuyuki

AU - Maeda, Yoshinobu

AU - Kiura, Katsuyuki

N1 - Publisher Copyright: 10.2169/internalmedicine.0890-18.

PY - 2019

Y1 - 2019

N2 - Pulmonary pleomorphic carcinoma (PPC) is a rare very aggressive subtype of non-small cell lung cancer. We herein report a case of PPC that showed a rapid response to nivolumab. The patient, whose multiple tumors had progressed very aggressively, was treated with nivolumab, an anti-programmed cell death-1 (PD-1) antibody. The tumors dramatically shrank after one cycle of nivolumab. The tumors were positive for programmed cell death ligand 1 (PD-L1). An immunohistochemical analysis revealed numerous PD-1+, CD68+ and CD206+ macrophages. This PD-1 antibody may be a good treatment option, especially in tumors that express PD-L1 and which show PD-1+ macrophage infiltration.

AB - Pulmonary pleomorphic carcinoma (PPC) is a rare very aggressive subtype of non-small cell lung cancer. We herein report a case of PPC that showed a rapid response to nivolumab. The patient, whose multiple tumors had progressed very aggressively, was treated with nivolumab, an anti-programmed cell death-1 (PD-1) antibody. The tumors dramatically shrank after one cycle of nivolumab. The tumors were positive for programmed cell death ligand 1 (PD-L1). An immunohistochemical analysis revealed numerous PD-1+, CD68+ and CD206+ macrophages. This PD-1 antibody may be a good treatment option, especially in tumors that express PD-L1 and which show PD-1+ macrophage infiltration.

KW - FGFR

KW - Immune checkpoint inhibitor

KW - PD-1

KW - PD-L1

KW - Pulmonary pleomorphic carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85063993478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063993478&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.0890-18

DO - 10.2169/internalmedicine.0890-18

M3 - Article

C2 - 30568113

AN - SCOPUS:85063993478

VL - 58

SP - 985

EP - 989

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 7

ER -

Rapid and long-term response of pulmonary pleomorphic carcinoma to nivolumab

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this